Efficacy of the 0.18 mg fluocinolone acetonide intravitreal implant in treating macular edema linked to non-infectious uveitis: Insights from a real-world analysis - Takeaways - MDSpire

Efficacy of the 0.18 mg fluocinolone acetonide intravitreal implant in treating macular edema linked to non-infectious uveitis: Insights from a real-world analysis

  • By

  • Cong Chen

  • Wen-Jing Zhang

  • Qin Ding

  • Shu-Min Shen

  • Ya Ye

  • Zhen Huang

  • Ming Yan

  • Yan-Ping Song

  • February 12, 2026

  • 0 min

Share

  • 1

    Macular edema is a major cause of vision loss in non-infectious uveitis, necessitating effective treatment options.

  • 2

    The 0.18 mg fluocinolone acetonide intravitreal implant was approved in China for chronic non-infectious uveitis affecting the posterior segment.

  • 3

    This study evaluated the clinical outcomes of the 0.18 mg FAi in 39 patients with non-infectious uveitis-related macular edema.

  • 4

    Patients demonstrated significant improvements in best-corrected visual acuity and central macular thickness after FAi treatment.

  • 5

    The study highlights the potential of the 0.18 mg FAi as a targeted therapy for managing macular edema in non-infectious uveitis.

Original Source(s)

Efficacy of the 0.18 mg fluocinolone acetonide intravitreal implant in treating macular edema linked to non-infectious uveitis: Insights from a real-world analysis

  • by Cong Chen, Wen-Jing Zhang, Qin Ding, Shu-Min Shen, Ya Ye, Zhen Huang, Ming Yan, Yan-Ping Song

  • February 12, 2026

Related Content

Immune-Mediated Inflammatory Diseases Following Pediatric Uveitis Diagnosis

Revealing Neurosarcoidosis in a Patient with Acute Zonal Occult Outer Retinopathy: A Case Study

Innovative One-Handed Syringe Handle Design for Anterior Chamber Paracentesis